Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors

Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors

Abstract Background The utilization of modern-immunotherapies, notably immune checkpoint inhibitors (ICIs), has increased markedly in patients with metastatic melanoma over the past decade and are recommended as standard treatment. Given their increasing adoption in routine care for melanoma, unders...

Full description

Bibliographic Details
Main Authors: Olajumoke A. Olateju, Zhen Zeng, J. Douglas Thornton, Osaro Mgbere, Ekere James Essien
Format: Article
Language:English
Published: BMC 2023-07-01
Series:BMC Cancer
Subjects:
Immunotherapy
Immune Checkpoint Inhibitors
Melanoma
Disparity
Utilization
Access
Online Access:https://doi.org/10.1186/s12885-023-11142-4

Similar Items

Similar Items